drug
ENV-6946
Phase 1updated 7mo agoby Enveda Biosciences Inc
Phase 1community read0 votes
indications
indications
IBD (Crohn's + UC)
all catalysts(0)
nothing on the calendar yet
News(4)
- 5 biggest venture capital raises of Q3 2026Venture capital continued to flow into biopharma in the third quarter, though experts pointed out that investors remained selective, preferring to put their money behind advanced and derisked asset…biospace · 1mo ago
- AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease pushTech darling Enveda has raised a total of $845 million in the past six years. The latest funding round is intended to pave the way for an IPO someday.biospace · 1mo ago
- Enveda reaps $311M series E to feed ambition to become a ‘household name’Enveda has raised a $311 million series E round, positioning the nature-derived drug discovery company to pursue its goal of becoming a household name over the next decade.fiercebiotech · 1mo ago
- Enveda’s exercise-simulating obesity tablet clears early clinical testTouting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.biospace · 3mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that